PONTI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.646
EU - Europa 9.148
AS - Asia 8.454
SA - Sud America 1.363
AF - Africa 191
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 17
Totale 41.840
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.178
GB - Regno Unito 3.257
SG - Singapore 2.836
CN - Cina 2.096
IT - Italia 1.890
HK - Hong Kong 1.090
BR - Brasile 1.046
VN - Vietnam 944
SE - Svezia 907
DE - Germania 767
FI - Finlandia 510
UA - Ucraina 481
RU - Federazione Russa 368
TR - Turchia 347
FR - Francia 345
CA - Canada 282
IN - India 213
KR - Corea 191
BG - Bulgaria 169
MX - Messico 138
ID - Indonesia 127
AR - Argentina 103
BD - Bangladesh 101
IQ - Iraq 90
NL - Olanda 81
JP - Giappone 67
IE - Irlanda 58
ZA - Sudafrica 57
EC - Ecuador 53
PL - Polonia 51
ES - Italia 47
AE - Emirati Arabi Uniti 41
PK - Pakistan 39
CO - Colombia 38
MY - Malesia 36
VE - Venezuela 33
CL - Cile 29
MA - Marocco 29
BE - Belgio 28
LT - Lituania 25
SA - Arabia Saudita 25
JO - Giordania 24
EG - Egitto 23
KE - Kenya 23
PH - Filippine 23
UZ - Uzbekistan 23
AT - Austria 22
PY - Paraguay 21
TH - Thailandia 21
CH - Svizzera 20
PE - Perù 19
RO - Romania 19
AU - Australia 18
CZ - Repubblica Ceca 15
NP - Nepal 15
AZ - Azerbaigian 13
TN - Tunisia 13
DZ - Algeria 12
PT - Portogallo 12
CR - Costa Rica 11
DO - Repubblica Dominicana 11
HU - Ungheria 11
IR - Iran 11
KZ - Kazakistan 11
BO - Bolivia 10
EU - Europa 10
IL - Israele 10
LU - Lussemburgo 10
PA - Panama 10
NO - Norvegia 9
PS - Palestinian Territory 9
NG - Nigeria 8
UY - Uruguay 8
LB - Libano 7
RS - Serbia 7
BH - Bahrain 6
AL - Albania 5
DK - Danimarca 5
ET - Etiopia 5
KG - Kirghizistan 5
MD - Moldavia 5
OM - Oman 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
GE - Georgia 4
GT - Guatemala 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
AO - Angola 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
HN - Honduras 3
HR - Croazia 3
LK - Sri Lanka 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SI - Slovenia 3
TT - Trinidad e Tobago 3
Totale 41.799
Salva come PNG Salva come JPEG
Città #
Fairfield 2.538
Southend 2.473
Ashburn 1.918
Santa Clara 1.849
Singapore 1.661
Woodbridge 1.579
Houston 1.168
Hong Kong 1.077
Seattle 979
Chandler 923
Wilmington 851
Jacksonville 831
Cambridge 810
Dearborn 786
Ann Arbor 661
Chicago 601
Nyköping 543
San Jose 541
Beijing 486
Hefei 472
Los Angeles 437
London 420
Helsinki 353
Modena 283
Ho Chi Minh City 281
Council Bluffs 253
Salt Lake City 246
The Dalles 229
Hanoi 227
San Diego 207
Princeton 203
Ottawa 192
Izmir 188
Seoul 179
New York 171
Sofia 167
Eugene 155
Shanghai 137
Lauterbourg 127
Tampa 123
Milan 121
Rome 117
Elk Grove Village 115
Buffalo 106
Dallas 99
Moscow 97
Orem 90
São Paulo 89
Jakarta 88
Bremen 81
Frankfurt am Main 75
Munich 74
Sterling 72
Lancaster 61
Dublin 55
Redwood City 54
Grafing 51
Columbus 49
Phoenix 49
Da Nang 47
Tokyo 46
Dong Ket 44
Haiphong 43
Bologna 40
Des Moines 39
Warsaw 39
Guangzhou 38
Miami 36
Rio de Janeiro 36
Norwalk 34
Boardman 33
Denver 33
Fremont 33
Chennai 32
Atlanta 30
Belo Horizonte 30
Detroit 30
Brooklyn 28
Baghdad 27
Dulles 27
Mexico City 27
Turin 26
Montreal 25
New Delhi 25
Redondo Beach 24
Dongguan 23
Nanjing 23
Curitiba 22
Palermo 22
Quito 22
San Mateo 22
Stockholm 22
Toronto 22
Kunming 21
Turku 21
Amman 20
Dhaka 20
Johannesburg 20
Mumbai 20
Pittsburgh 20
Totale 30.060
Salva come PNG Salva come JPEG
Nome #
Mutazioni somatiche di BRAF in pazienti affetti da melanoma maligno metastatico ed efficacia clinica degli approcci terapeutici a bersaglio molecolare con inibitori di BRAF 596
Neoplasie maligne e benigne associate al melanoma multiplo: coinvolgimento di MITF, PTEN and CDKN2A nella cancerogenesi melanocitaria multipla. 550
Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. 443
Reticular grey-blue areas of regression as a dermoscopic marker of melanoma in situ. 436
Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas 436
Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA) 436
Attitude of the Italian general population towards prevention and screening of the most common tumors, with special emphasis on colorectal malignancies. 434
Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes 434
The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients 423
BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-asociated polyposis pedigrees 423
Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or Keratoacanthomas 405
"Collision" metastasis from unknown primary squamous cell carcinoma and papillary microcarcinoma of thyroid presenting as lateral cervical cystic mass 402
Brooke-Spiegler syndrome tumor spectrum beyond the skin: a patient carrying germline R936X CYLD mutation and a somatic CYLD mutation in Brenner tumor 401
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 398
Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients 386
Different phenotypes in Muir-Torre Syndrome: clinical and biomolecular characterization in two italian families 385
Brooke-Spiegler syndrome: Report of two cases not associated with a mutation in the CYLD and PTCH tumor-suppressor genes 372
Aetiology of colorectal cancer and relevance of monogenic inheritance. 365
Caso di Neurofibromatosi diagnosticata a 71 anni 361
Diagnostic and pathogenetic role of café-au-lait macules in nevoid basal cell carcinoma syndrome 361
A novel CYLD germline mutation in Brooke-Spiegler syndrome. 359
Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. 358
Seminal Cell-Free DNA Assessment as a Novel Prostate Cancer Biomarker 357
Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer 356
Variegated Dermoscopy of in situ Melanoma. 354
Congenital Glioblastoma multiforme and eruptive disseminated Spitz nevi 349
Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC. 349
Novel PTCH1 Mutations in Patients with Keratocystic Odontogenic Tumors Screened for Nevoid Basal Cell Carcinoma (NBCC) Syndrome. 347
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 340
Hereditary trichilemmal cysts: a proposal for the assessment of diagnostic clinical criteria 340
Ameloblastoma: A neglected criterion for nevoid basal cell carcinoma (Gorlin) syndrome 338
Giant elephantiasis neuromatosa in the setting of neurofibromatosis type 1: A case report 337
A mononucleotide markers panel to identify hMLH1/hMSH2 germline mutations 336
Unicystic ameloblastoma associated with the novel K729M PTCH1 mutation in a patient with nevoid basal cell carcinoma (Gorlin) syndrome. 334
Immunohistochemical expression of MYH protein can be used to identify patients with MYH-associated polyposis 334
Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis 330
PTCH1 germline mutations and the basaloid follicular hamartoma values in the tumor spectrum of basal cell carcinoma syndrome (NBCCS) 329
Hypomelanosis of Ito with a trisomy 2 mosaicism: a case report 328
Grey-blue regression in melanoma in situ-evaluation on 111 cases. 328
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 327
Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology 327
Biomarkers associated with COVID-19 disease progression 324
High Magnification Digital Dermoscopy of Basal Cell Carcinoma: A Single-centre Study on 400 cases. 323
Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy 323
Skeletal and cranio-facial signs in Gorlin syndrome from ancient Egypt to the modern age: Sphenoid asymmetry in a patient with a novel PTCH1 mutation 318
NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies 316
BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features? 316
Dermoscopy of small melanomas: just a miniaturized dermoscopy? 315
Epidemiology of colorectal cancer: the 21-year experience of a specialised registry. 314
Confocal microscopy characterization of BRAFV600E mutated melanomas 313
The impact of histopathologic diagnosis on the proper management of testis neoplasms. 312
Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients 310
Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome 310
Fluorescence in-situ hybridization and dermoscopy in the assessment of controversial melanocytic tumors. 307
Identification of Muir-Torre Syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability and immunohistochemistry 306
Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas 297
Mismatch Repair Gene Deficiency and Genetic Anticipation in Lynch Syndrome 294
Cancer-associated genodermatoses: Skin neoplasms as clues to hereditary tumor syndromes. 292
Microsatellite instability and colorectal cancer prognosis. 291
Desmoplastic melanoma: a challenge for the oncologist 289
Seminal cell-free DNA assessment as a novel prostate cancer biomarker 287
Seminal cell free DNA concentration levels discriminate between prostate cancer and benign prostatic hyperplasia 286
Clinico-pathological and biomolecular findings in Italian patients with multiple cutaneous neurofibromas. 284
Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma 282
Multiphoton laser tomography and fluorescence lifetime imaging of melanoma: morphologic features and quantitative data for sensitive and specific non-invasive diagnostics. 279
Fibroepithelioma of Pinkus: Solitary tumor or sign of a complex gastrointestinal syndrome 277
Wall paintings facies and their possible genetic correlates in the ancient Pompeii: A bio-anthropologic message from the past? 270
Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry. 269
p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome 269
Role of microsatellite instability, immunohistochemistry and Mismatch Repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre Syndrome. 268
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 267
Can noninvasive imaging tools potentially predict the risk of ulceration in invasive melanomas showing blue and black colors? 267
Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers. 266
Diagnosis of hereditary non-polyposis colorectal cancer (HNPCC) [2] (multiple letters) 262
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma 261
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 261
Alternative marker panel for microsatellite instability analysis in detection of constitutional MLH1 and MSH2 mutations. 261
Skeletal stigmata as keys to access to the composite and ancient Gorlin-Goltz syndrome history: The Egypt, Pompeii and Herculaneum lessons 260
Seminal cell-free DNA molecular profile as a novel diagnostic and prognostic prostate cancer biomarkers 259
Oral mucosal stigmata in hereditary-cancer syndromes: From germline mutations to distinctive clinical phenotypes and tailored therapies 258
L'immunoistochimica delle proteine del mismatch repair può essere un utile test per identificare i pazienti HNPCC? 255
Genetic testing among high-risk individuals in families with hereditary non polyposis colorectal cancer 254
Biological characterization of mucinous carcinoma of the colon and rectum 254
Multiphoton laser tomography and fluorescence lifetime imaging of basal cell carcinoma: morphologic features for non-invasive diagnostics 254
The dermoscopic variability of pigment network in melanoma in situ. 253
Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study on 140 cases. 253
Are the neck malignant melanomas different from the ones affecting the head? Clinicopathologic, dermoscopic and prognostic findings 251
Relationship between histological and computer based assessment of melanoma diameter and thickness in head & neck vs. trunk melanoma. 250
Diagnosis of BCC by multiphoton laser tomography. 246
Erratum: Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanoma (Disease Markers) 243
Stem cell properties in cell cultures from different stage of melanoma progression. 241
Distinctive clinical and dermoscopic features of BRAFp.V600K mutated melanomas. 240
Microsatellite instability, immunohistochemistry and germline mismatch repair gene mutations for the diagnosis of Muir-Torre syndrome in immunosuppressed patients 239
The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. 239
Alternative marker panel for Microsatellite Instability analysis in deection of contitutional MLH1 and MSH2 mutations. 237
Proteomic Analysis of PTCH1+/- Fibroblast Lysate and Conditioned Culture Media Isolated from the Skin of Healthy Subjects and Nevoid Basal Cell Carcinoma Syndrome Patients. 230
Italian Euromelanoma Day Screening Campaign (2005-2007) and the planning of melanoma screening strategies. 229
Muir-Torre Syndrome and founder Mismatch Repair genes mutations: A long gone historical genetic challenge 228
High-resolution imaging of basal cell carcinoma: a comparison between multiphoton microscopy with fluorescence lifetime imaging and reflectance confocal microscopy. 225
Ameloblastoma as criterion for Nevoid Basal Cell Carcinoma (Gorlin) Syndrome identification 224
Totale 31.712
Salva come PNG Salva come JPEG
Categoria #
all - tutte 156.534
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 156.534
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.165 0 0 0 0 0 0 0 0 0 537 289 339
2021/20223.306 260 412 347 182 73 176 175 184 360 238 553 346
2022/20232.776 357 345 210 236 329 383 59 255 316 51 133 102
2023/20241.862 86 90 129 174 383 193 193 216 53 48 100 197
2024/20256.728 193 63 92 405 1.297 1.049 455 429 707 365 677 996
2025/202611.466 637 376 887 1.800 2.756 810 1.377 615 1.183 1.025 0 0
Totale 42.247